XTreme 200 Human Liver Microsomes Lot No Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose
|
|
|
- Chastity McCoy
- 5 years ago
- Views:
Transcription
1 XTreme 200 Human Liver Microsomes Lot No Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose H ml at 20 mg/ml H ml at 20 mg/ml H ml at 20 mg/ml H ml at 20 mg/ml Specific Content and Enzyme Activities Content / Rate Cytochrome P450 content (nmol/mg protein) Cytochrome b5 content (nmol/mg protein) NADPH-cytochrome c reductase (nmol/mg protein/min) 214 ± 2 Enzyme Marker Substrate Reaction [S] (µm) Rate (pmol/mg protein/min) CYP1A2 Phenacetin O-dealkylation ± 14 CYP2A6 Coumarin 7-hydroxylation ± 120 CYP2B6 Bupropion hydroxylation ± 29 CYP2C8 Amodiaquine N-dealkylation ± 90 CYP2C9 Diclofenac 4'-hydroxylation ± 50 CYP2C19 S-Mephenytoin 4'-hydroxylation ± 3.5 CYP2D6 Dextromethorphan O-demethylation ± 11 CYP2E1 Chlorzoxazone 6-hydroxylation ± 80 CYP2J2 Ebastine hydroxylation ± 8 CYP3A4/5 Testosterone 6β-hydroxylation ± 440 CYP3A4/5 Midazolam 1'-hydroxylation ± 26 CYP4A11 Lauric acid 12-hydroxylation ± 50 FMO Benzydamine N-oxygenation ± 29 UGT1A1 17β-Estradiol 3-glucuronidation ± 10 UGT1A3 Chenodeoxycholic acid 24O-glucuronidation ± 2.4 UGT1A4 Trifluoperazine glucuronidation ± 10 UGT1A6 1-Naphthol glucuronidation ± 380 UGT1A9 Propofol glucuronidation ± 90 UGT2B7 Morphine 3-glucuronidation ± 270 UGT2B17 17βO-Testosterone glucuronidation ± 86 Characterization is performed when the first lot of a product from a given subcellular fraction (e.g., S9) is prepared. Subsequent lots are subject to a verification test only. Values for enzyme activities were determined at a single substrate concentration and are mean + standard deviation of three or more determinations. To measure cytochrome P450 (CYP) activity, liver microsomes (50 µg/ml) were incubated in triplicate at 37 ± 1 C for 10 minutes in potassium phosphate buffer (50 mm, ph 7.4), containing MgCl2 (3.0 mm), EDTA (1.0 mm), NADP (1.0 mm), glucose-6-phosphate (5.0 mm), glucose-6-phosphate dehydrogenase (1 Unit/mL) and marker substrate, at the final concentrations indicated. Metabolite formation was determined by validated LC-MS/MS methods with deuterated metabolites as internal standards. FMO activity was measured under similar conditions except the protein concentration was 1 mg/ml and the buffer was 49 mm Tricine (ph 8.5) To measure UDP-glucuronosyltransferase (UGT) activity, liver microsomes ( µg/ml) were incubated in triplicate at 37 ± 1 C for 5 or 10 minutes in Tris-HCl (100 mm, ph 7.7 at 37 C), CHAPS (0.5 mm), EDTA (1.0 mm), MgCl2 (10 mm), D-saccharic acid 1,4-lactone (100 µm), uridine diphosphate-glucuronic acid (8.0 mm) and marker substrate at the final concentrations indicated. Each donor is equally represented in this pool. Store at -80 C CAUTION: This sample should be considered as a potential biohazard and universal precautions should be followed. Intended for in vitro use only. Datasheet prepared 19 December 2018
2 Kinetic constants for CYP enzyme activities in human liver microsomes (pool of 200) Enzyme Marker Substrate Kinetic Constants CL int: Intrinsic clearance (i.e., Vmax/Km). Km (µm) Kinetic constants are mean + standard deviation of three or more determinations. Vmax (pmol/mg protein/min) CL int (µl/mg protein/min) CYP1A2 Phenacetin 61.2 ± ± [S] range: µm CYP2A6 Coumarin ± ± [S] range: µm CYP2B6 Bupropion 113 ± ± [S] range: µm CYP2B6 Efavirenz 5.10 ± ± [S] range: µm CYP2C8 Amodiaquine 2.50 ± ± (low protein concentration) [S] range: µm CYP2C9 Diclofenac 8.45 ± ± [S] range: µm CYP2C19 S-Mephenytoin 69.6 ± ± [S] range: µm CYP2D6 Dextromethorphan 9.07 ± ± [S] range: µm CYP2E1 Chlorzoxazone 61.2 ± ± [S] range: µm CYP3A4/5 Testosterone 76.5 ± ± [S] range: µm CYP3A4/5 Midazolam 2.86 ± ± [S] range: 1-40 µm CYP4A11 Lauric acid 1.35 ± ± [S] range: µm Page 2 of 7
3 248 M 29 Hispanic Head trauma 255 M 46 Hispanic Anoxia 262 M 42 Caucasian Cerebrovascular accident 310 F 52 Caucasian Cerebrovascular accident 342 F 31 Caucasian Anoxia 375 M 23 Caucasian Head trauma 380 M 47 Caucasian Head trauma 384 M 53 Caucasian Anoxia 386 M 32 Caucasian Head trauma 400 F 42 Caucasian Anoxia 402 M 32 Caucasian Anoxia 405 M 32 Caucasian Anoxia 407 M 69 Caucasian Cerebrovascular accident 408 M 32 Caucasian Head trauma 409 F 63 Hispanic Cerebrovascular accident 411 M 55 Caucasian Anoxia 412 M 66 Caucasian Cerebrovascular accident 418 F 62 Hispanic Anoxia 437 M 62 Caucasian Cerebrovascular accident 438 M 56 Caucasian Head trauma 439 F 78 Caucasian Anoxia 448 F 58 Caucasian Anoxia 451 M 58 Caucasian Cerebrovascular accident 453 F 25 Caucasian Anoxia 460 F 43 Hispanic Cerebrovascular accident 461 F 74 Caucasian Cerebrovascular accident 466 M 48 Caucasian Anoxia 474 M 33 Caucasian Anoxia 475 M 27 Caucasian Anoxia 479 M 65 Caucasian Anoxia 484 F 55 Caucasian Cerebrovascular accident 487 M 48 Caucasian Head trauma 488 M 57 Caucasian Head trauma 490 F 60 Caucasian Cerebrovascular accident 496 F 58 Caucasian Cerebrovascular accident 499 F 55 Caucasian Cerebrovascular accident 506 F 48 Caucasian Cerebrovascular accident 515 F 59 Caucasian Cerebrovascular accident 530 F 64 Caucasian Head trauma 532 M 26 Caucasian Head trauma 533 M 28 African American Anoxia 536 F 34 Caucasian Anoxia 542 F 53 Caucasian Cerebrovascular accident 543 F 58 Caucasian Anoxia Page 3 of 7
4 544 M 45 Caucasian Anoxia 546 F 53 Caucasian Cerebrovascular accident 548 F 61 Caucasian Anoxia 552 M 40 American Indian Head trauma 554 F 43 Caucasian Anoxia 555 M 69 Caucasian Anoxia 556 F 49 Caucasian Cerebrovascular accident 558 M 50 Caucasian Anoxia 561 M 55 African American Cerebrovascular accident 569 M 60 Caucasian Anoxia 572 M 68 Caucasian Cerebrovascular accident 574 M 63 Caucasian Cerebrovascular accident 576 F 55 Caucasian Cerebrovascular accident 577 F 23 Caucasian Cerebrovascular accident 582 F 60 Caucasian Anoxia 589 F 55 Caucasian Cerebrovascular accident 594 F 51 Caucasian Cerebrovascular accident 596 F 17 Caucasian Head trauma 603 F 67 Caucasian Head trauma 605 F 49 Caucasian Cerebrovascular accident 608 F 54 Caucasian Anoxia 611 F 25 Caucasian Cerebrovascular accident 617 F 52 Caucasian Cerebrovascular accident 619 F 45 Caucasian Cerebrovascular accident 625 F 39 Caucasian Anoxia 628 F 62 Caucasian Cerebrovascular accident 634 F 63 Caucasian Cerebrovascular accident 659 F 33 Hispanic Anoxia 686 F 52 Caucasian Anoxia 706 F 53 Caucasian Cerebrovascular accident 715 M 21 Caucasian Head trauma 726 F 48 Caucasian Cerebrovascular accident 728 M 39 Caucasian Cerebrovascular accident 729 F 66 Caucasian Head trauma 736 F 46 Caucasian Anoxia 744 M 57 Caucasian Cerebrovascular accident 750 F 53 Caucasian Anoxia 751 M 29 Caucasian Anoxia 755 F 39 Caucasian Anoxia 758 F 55 Caucasian Cerebrovascular accident 761 M 70 Caucasian Cerebrovascular accident 765 F 39 Caucasian Cerebrovascular accident 766 F 38 Caucasian Anoxia Page 4 of 7
5 769 M 58 Caucasian Head trauma 772 M 46 Caucasian Anoxia 773 M 46 Caucasian Head trauma 778 M 61 Caucasian Cerebrovascular accident 780 F 48 African American Cerebrovascular accident 788 F 58 Caucasian Cerebrovascular accident 794 M 36 Hispanic Head trauma 807 F 47 Caucasian Cerebrovascular accident 808 M 57 Caucasian Cerebrovascular accident 810 M 37 Caucasian Head trauma 811 M 16 Caucasian Head trauma 812 M 73 Caucasian Cerebrovascular accident 814 F 65 Caucasian Cerebrovascular accident 815 M 52 Caucasian Anoxia 817 F 31 Caucasian Anoxia 818 M 48 Hispanic Cerebrovascular accident 819 F 49 Caucasian Head trauma 820 F 65 Caucasian Cerebrovascular accident 821 F 51 Caucasian Anoxia 839 F 25 African American Cerebrovascular accident 840 M 77 Caucasian Cerebrovascular accident 841 M 74 Caucasian Head trauma 842 F 60 Caucasian Anoxia 847 F 55 Caucasian Cerebrovascular accident 851 F 47 Caucasian Cerebrovascular accident 956 F 68 African American Anoxia 962 M 47 Caucasian Anoxia 966 F 53 Caucasian Head trauma 968 M 54 Caucasian Cerebrovascular accident 970 M 68 Caucasian Anoxia 973 F 63 Caucasian Cerebrovascular accident 974 M 19 Hispanic Anoxia 975 M 46 Hispanic Cerebrovascular accident 976 F 61 Caucasian Head trauma 977 M 54 Caucasian Head trauma 978 F 56 Hispanic Cerebrovascular accident 982 F 30 Caucasian Anoxia 983 M 49 Caucasian Anoxia 985 F 58 Caucasian Cerebrovascular accident 989 F 47 Caucasian Cerebrovascular accident 990 M 38 Caucasian Cerebrovascular accident 994 F 73 Caucasian Cerebrovascular accident 995 F 45 Caucasian Cerebrovascular accident Page 5 of 7
6 996 F 10 Caucasian Anoxia 997 M 63 Caucasian Anoxia 998 F 63 Caucasian Cerebrovascular accident 999 F 19 Hispanic Anoxia 1001 F 50 American Indian Cerebrovascular accident 1002 M 48 African American Cerebrovascular accident 1003 F 75 Caucasian Cerebrovascular accident 1004 F 45 Caucasian Head trauma 1005 M 45 Caucasian Cerebrovascular accident 1006 M 50 Caucasian Anoxia 1007 M 20 Caucasian Head trauma 1008 M 36 Hispanic Cerebrovascular accident 1009 M 22 Caucasian Cerebrovascular accident 1010 M 63 Caucasian Cerebrovascular accident 1011 M 65 Caucasian Cerebrovascular accident 1012 M 41 Caucasian Anoxia 1013 M 51 Caucasian Cerebrovascular accident 1014 M 55 Caucasian Anoxia 1015 M 59 Caucasian Cerebrovascular accident 1016 M 64 Hispanic Head trauma 1018 M 59 Caucasian Anoxia 1020 F 24 Caucasian Cerebrovascular accident 1022 M 41 Caucasian Anoxia 1024 F 59 Caucasian Anoxia 1025 M 57 Caucasian Cerebrovascular accident 1026 F 55 African American Head trauma 1027 F 63 Caucasian Cerebrovascular accident 1028 F 51 African American Cerebrovascular accident 1030 M 67 Caucasian Cerebrovascular accident 1032 M 64 Caucasian Cerebrovascular accident 1033 F 55 Caucasian Cerebrovascular accident 1042 M 51 Caucasian Cerebrovascular accident 1044 F 19 Caucasian Anoxia 1045 M 48 Caucasian Cerebrovascular accident 1046 M 49 Caucasian Anoxia 1047 M 53 Hispanic Cerebrovascular accident 1051 F 57 African American Cerebrovascular accident 1054 M 19 Caucasian Head trauma 1055 F 29 African American Head trauma 1060 M 49 Hispanic Cerebrovascular accident 1061 M 40 Hispanic Cerebrovascular accident 1063 M 43 Hispanic Head trauma 1066 M 60 Caucasian Cerebrovascular accident Page 6 of 7
7 1068 M 43 Caucasian Head trauma 1069 M 39 Caucasian Cerebrovascular accident 1074 F 51 African American Cerebrovascular accident 1075 M 56 Caucasian Cerebrovascular accident 1077 F 57 Caucasian Head trauma 1079 M 41 Caucasian Anoxia 1081 M 55 Caucasian Cerebrovascular accident 1084 M 52 Caucasian Cerebrovascular accident 1087 M 51 African American Cerebrovascular accident 1088 F 61 Caucasian Cerebrovascular accident 1089 M 55 Caucasian Anoxia 1090 M 49 Caucasian Cerebrovascular accident 1091 M 74 Caucasian Cerebrovascular accident 1093 F 48 Caucasian Cerebrovascular accident 1094 M 59 African American Cerebrovascular accident 1095 F 60 Caucasian Cerebrovascular accident 1097 M 36 Caucasian Cerebrovascular accident 1098 M 54 Caucasian Head trauma 1101 F 47 Caucasian Anoxia 1102 M 48 Caucasian Cerebrovascular accident 1106 F 20 Caucasian Cerebrovascular accident 1107 F 55 Caucasian Cerebrovascular accident 1108 F 45 African American Cerebrovascular accident 1117 F 66 Caucasian Cerebrovascular accident 1130 F 65 Caucasian Cerebrovascular accident 1155 F 43 Caucasian Cerebrovascular accident 1157 F 59 Hispanic Head trauma Serology information Cytomegalovirus: 124 of 200 donors tested positive and 1 donor was not determined. RPR*: 200 donors tested negative. HIV, HTLV, HbsAg, and HCV**: All donors tested negative. * Rapid Plasma Reagin ** Antibody to Human Immunodeficiency Virus, Antibody to Human T Cell Lymphotropic Virus, Hepatitis B Surface Antigen, Antibody to Hepatitis C Virus, respectively. Page 7 of 7
Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338
Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338 S. Furuta 1, E. Kamada 1, T. Sugimoto 1, Y. Kawabata 1, X. C. Wu 2, J. Skibbe 3, E. Usuki 3, A. Parkinson 3 and
Arena Pharmaceuticals, Inc., Department of Drug Metabolism and Pharmacokinetics, San Diego, California
1521-009X/12/4004-761 771$25.00 DRUG METABOLISM AND DISPOSITION Vol. 40, No. 4 Copyright 2012 by The American Society for Pharmacology and Experimental Therapeutics 43414/3759637 DMD 40:761 771, 2012 Identification
CYTOCHROME P450: Structure-Function
MEDCH 527 AE Jan. 4-6, 2017 CYTCHME P450: Structure-Function 1. General P450 Characteristics and Taxonomy 2. Human P450s Substrate and Inhibitor Selectivities 3. Structure-Function Aspects of Ligand Binding,
High-Throughput CYP Inhibition Screening with Drug Probe Substrates: The RapidFire Advantage
High-Throughput CYP Inhibition Screening with Drug Probe Substrates: The RapidFire Advantage David M. Stresser, Ph.D. Program Manager BD Gentest SM Contract Research Services November 11, 2009 Presentation
In vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases
In vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases (UGTs) Josiane de Oliveira Cardoso, Regina Vincenzi Oliveira, Jessica Bo Li Lu Zeruesenay Desta Department
Strategies for In Vitro Metabolic Stability Testing. Christopher Patten, PhD. BD Biosciences December 2, 2009
Strategies for In Vitro Metabolic Stability Testing Christopher Patten, PhD BD Biosciences December 2, 2009 Presentation Overview Overview of in vitro metabolic stability testing In vitro model systems
Pilot experiments to investigate the glucuronidation of axitinib with human liver microsomes.
Zientek MA, Goosen TC, Tseng E, Lin J, Bauman JN, Walker GS, Kang P, Jiang Y, Freiwald S, Neul D and Smith BJ. In Vitro Kinetic Characterization of Axitinib Metabolism. Drug Metab Dispos. Supplemental
An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes
9-9556/11/398-137 1387$25. DRUG METABOLISM AND DISPOSITION Vol. 39, No. 8 Copyright 211 by The American Society for Pharmacology and Experimental Therapeutics 38596/3724 DMD 39:137 1387, 211 Printed in
MEDCH/PCEUT 527 ADVANCED DRUG METABOLISM 2019 Course Coordinators: Allan Rettie and Ken Thummel When/ Where:
MEDCH/PCEUT 527 ADVACED DRUG METABLISM 2019 Course Coordinators: Allan Rettie and Ken Thummel When/ Where: 2.30 4.00 pm MWF in H074 Date Topic Instructor Jan 7 Introduction Rettie/Thummel Jan 9 P450 I:
PREDICTING PHARMACOKINETICS FOLLOWING TOPICAL APPLICATION USING NON-ANIMAL METHODS IAN SORRELL, MI-YOUNG LEE, RICHARD CUBBERLEY
PREDICTING PHARMACOKINETICS FOLLOWING TOPICAL APPLICATION USING NON-ANIMAL METHODS IAN SORRELL, MI-YOUNG LEE, RICHARD CUBBERLEY UNILEVER APPLICATIONS KINETICS Need for estimates of local and systemic concentrations
Chapter 4. Drug Biotransformation
Chapter 4 Drug Biotransformation Drug Biotransformation 1 Why is drug biotransformation necessary 2 The role of biotransformation in drug disposition 3 Where do drug biotransformation occur 4 The enzymes
Supplemental material to this article can be found at:
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2011/06/14/dmd.111.039776.dc1 0090-9556/11/3909-1658 1667$25.00 DRUG METABOLISM AND DISPOSITION Vol. 39,
The metabolism of 1 - and 4-hydroxymidazolam by glucuronide conjugation is. largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7
DMD Fast This article Forward. has not Published been copyedited on and August formatted. 16, The 2010 final version as doi:10.1124/dmd.110.035295 may differ from this version. The metabolism of 1 - and
ANTHONY J. LEE, JOSEPH W. KOSH, ALLAN H. CONNEY, 1 and BAO TING ZHU. ABSTRACT We characterized the NADPH-dependent metabolism of 17 estradiol
0022-3565/01/2982-420 432$3.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 298, No. 2 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 3751/916932
Sorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and
Supplemental Methods Chemicals and Reagents Sorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and isotopically-labeled 13 C- 2 H 3 -sorafenib (labeled atoms on N-methyl position)
Effect of BD Matrigel Matrix Overlay and BD Matrigel Matrix Thin Coat on CYP450 Activities in Cryo Human Hepatocytes. Rongjun Zuo.
Effect of BD Matrigel Matrix Overlay and BD Matrigel Matrix Thin Coat on CYP450 Activities in Cryo Human Hepatocytes Rongjun Zuo November 10, 2010 Topics Overview of Hepatocyte Products P450 Induction
Chris Bohl, Ph.D. Global Technical Support Manager- Products
Chris Bohl, Ph.D. Global Technical Support Manager- Products cbohl1@xenotechllc.com Sekisui XenoTech Overview GLP-compliant in vitro ADME-DMPK CRO founded in 1994 at the University of Kansas Medical Center
Metabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes
Virginia Commonwealth University VCU Scholars Compass Medicinal Chemistry Publications Dept. of Medicinal Chemistry 216 Metabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes Zhongnv
Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 Definition Phenotyping is quantifying the in vivo activity
Culture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug Interaction. Chuang Lu
Culture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug nteraction Chuang Lu Millennium, The Takeda Oncology Company Cambridge, MA, USA DD 205, Seattle, 6/29/205
Metabolism of 1 - and 4-Hydroxymidazolam by Glucuronide Conjugation Is Largely Mediated by UDP-Glucuronosyltransferases 1A4, 2B4, and 2B7
0090-9556/10/3811-2007 2013$20.00 DRUG METABOLISM AND DISPOSITION Vol. 38, No. 11 Copyright 2010 by The American Society for Pharmacology and Experimental Therapeutics 35295/3635725 DMD 38:2007 2013, 2010
Carolina Säll, J. Brian Houston, and Aleksandra Galetin
1521-9X/12/47-1279 1289$25. DRUG METABOLISM AND DISPOSITION Vol. 4, No. 7 Copyright 212 by The American Society for Pharmacology and Experimental Therapeutics 45286/3773739 DMD 4:1279 1289, 212 A Comprehensive
In vitro assay of six UGT isoforms in human liver microsomes, using cocktails of probe substrates and LC-MS/MS
Supplemental data for Drug Metabolism and Disposition In vitro assay of six UGT isoforms in human liver microsomes, using cocktails of probe substrates and LC-MS/MS Kyung-Ah Seo, Hyo-Ji Kim, Eun Sook Jeong,
Corydaline Inhibits Multiple Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes
Molecules 2011, 16, 6591-6602; doi:10.3390/molecules16086591 Article OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Corydaline Inhibits Multiple Cytochrome P450 and UDP-Glucuronosyltransferase
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney
DMD Fast This Forward. article has not Published been copyedited on and January formatted. 24, The 2012 final version as doi:10.1124/dmd.111.043984 may differ from this version. Characterization of in
Received: 2 August 2017; Accepted: 13 September 2017; Published: 21 September 2017
Article Inhibitory Effect of Selaginellins from Selaginella tamariscina (Beauv.) Spring against Cytochrome P450 and Uridine 5 -Diphosphoglucuronosyltransferase Isoforms on Human Liver Microsomes Jae-Kyung
Michelle Schaefer, Gerhard Schänzle, Daniel Bischoff, and Roderich D. Süssmuth.
Upcyte Human Hepatocytes: a Potent In Vitro Tool for the Prediction of Hepatic Clearance of Metabolically Stable Compounds. Michelle Schaefer, Gerhard Schänzle, Daniel Bischoff, and Roderich D. Süssmuth.
XenoTech LLC, Lenexa, KS, USA. Full text of this paper is available at
Drug Metab. Pharmacokinet. 25 (1): 16 27 (2010). Review System-Dependent Outcomes during the Evaluation of Drug Candidates as Inhibitors of Cytochrome P450 (CYP) and Uridine Diphosphate Glucuronosyltransferase
Supplemental material to this article can be found at:
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2016/11/07/dmd.116.073411.dc1 1521-009X/45/1/86 108$25.00 http://dx.doi.org/10.1124/dmd.116.073411 DRUG
Discovery of a highly selective CYP3A4 inhibitor suitable for reaction. phenotyping studies and differentiation of CYP3A4 and CYP3A5
DMD Fast This article Forward. has not been Published copyedited on and June formatted. 13, The 2012 final version as doi:10.1124/dmd.112.046144 may differ from this version. Discovery of a highly selective
Pharmacokinetics and Metabolism (Toxicokinetics)
Pharmacokinetics and Metabolism (Toxicokinetics) Gerd Bode, M.D.,Ph.D. Lecturer and Consultant gerd-bode@t-online.de 1 Preclinical Disciplines Pharmacology Research on desirable effects by in vitro and
Cryo Characterization Report (CCR)
Human Cryopreserved Hepatocytes Lot number: HUM4061B Date: October 19, 2014 Cryo Characterization Report (CCR) Lot Overview Qualification Catalog Number Quantity Cryopreserved human hepatocytes, Qualyst
Objectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy
Objectives Making, Drug Interactions, & Pharmacogenetics Easy Anthony J. Busti, MD, PharmD, FNLA, FAHA Describe the differences between phase I and phase II metabolic pathways. Identify the most common
Cover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/36511 holds various files of this Leiden University dissertation Author: Brill, Margreke Title: Concepts and applications for evidence-based dosing in morbidly
Enhanced method development workflow for modern LC and SFC
Enhanced method development workflow for modern LC and SFC Davy GUILLARME 18 th of September 2014 What can be done with modern LC? MONOLITHS HIGH TEMPERATURE 1 000 000 plates 12 m column 120 C.60 0.40
Cryopreserved Enterocytes for the Evaluation of Drug-Drug and Food- Drug Interactions
Cryopreserved Enterocytes for the Evaluation of Drug-Drug and Food- Drug Interactions Albert P. Li, Ph. D. In Vitro ADMET Laboratories Inc. Columbia, MD and Malden, MA Why Enterocytes Key cell type for
Sylvie Klieber, Catherine Arabeyre-Fabre, Patricia Moliner, Eric Marti, Martine Mandray, Robert Ngo, Celine Ollier, Priscilla Brun & Gerard Fabre
ORIGINAL ARTICLE Identification of metabolic pathways and enzyme systems involved in the in vitro human hepatic metabolism of dronedarone, a potent new oral antiarrhythmic drug Sylvie Klieber, Catherine
EFFECT OF OBESITY ON HEPATIC DRUG METABOLISM A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY
EFFECT OF OBESITY ON HEPATIC DRUG METABOLISM A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Manoj Shriram Chiney IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
Constitutive Regulation of P450s by Endocrine Factors
Constitutive Regulation of P450s by Endocrine Factors References: Meyer UA. Endo-xenobiotic crosstalk and the regulation of cytochromes P450. Drug Metab Rev 39:639-46, 2007. Waxman DJ and O Connor C. Growth
Novel Human-Based In Vitro Liver and Intestinal Technologies for Drug Development
Novel Human-Based In Vitro Liver and Intestinal Technologies for Drug Development Albert P. Li, Ph. D., President and CEO In Vito ADMET Laboratories Inc. Columbia, MD and Malden, MA lialbert@invitroadmet.com
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu , Republic of Korea 3
Evidence-Based Complementary and Alternative Medicine Volume 2012, Article ID 650718, 7 pages doi:10.1155/2012/650718 Research Article Effect of a New Prokinetic Agent DA-9701 Formulated with Corydalis
CYTOCHROME P-450 3A4 AND 2C8 ARE INVOLVED IN ZOPICLONE METABOLISM
0090-9556/99/2709-1068 1073$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 9 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. CYTOCHROME P-450
Efficient Liver Targeting and Uptake by Novel Tenofovir Prodrug, CMX157, For the Treatment of Hepatitis B
Efficient Liver Targeting and Uptake by Novel Tenofovir Prodrug, CMX157, For the Treatment of Hepatitis B R Rush 1, J Greytok 2, T Matkovits 2, R Driz 2, JZ Sullivan-Bólyai 2, and D Standring 3 1 Allon
Influence of fluvoxamine on carvedilol metabolism and plasma disposition in vitro and in vivo experiments
Influence of fluvoxamine on carvedilol metabolism and plasma disposition in vitro and in vivo experiments MARIA BIANCA ABRUDAN* 1, DANA MARIA MUNTEAN 1, DANIELA SAVETA POPA 2, LAURIAN VLASE 1, ANA-MARIA
Receiving Cryopreserved Human Hepatocytes
Receiving Cryopreserved Human Hepatocytes TECHNICAL BULLETIN Purpose The purpose of this bulletin is to provide instructions and recommendations for the proper receiving and transfer of cryopreserved human
Inhibitory Effects of Garcinia cambogia Extract on CYP2B6 Enzyme Activity
Inhibitory Effects of Garcinia cambogia Extract on CYP2B6 Enzyme Activity Authors Jun Sang Yu 1 *, Min Sun Choi 1 *, Jong Suk Park 1, Shaheed Ur Rehman 2, Katsunori Nakamura 3, Hye Hyun Yoo 1 Affiliations
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2006.02627.x An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors,
Title Page. CYP-mediated sulfoximine de-imination of AZD6738. Authors: Barry C Jones, Roshini Markandu, Chungang Gu and Graeme Scarfe.
Title Page CYP-mediated sulfoximine de-imination of AZD6738 Authors: Barry C Jones, Roshini Markandu, Chungang Gu and Graeme Scarfe Addresses: Oncology IMED, Astrazeneca, Cambridge, UK, CB4 0WG (BCJ, RM
Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 49-OH-bupropion in vitro
1521-009X/44/10/1709 1719$25.00 http://dx.doi.org/10.1124/dmd.116.072363 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:1709 1719, October 2016 Copyright ª 2016 by The Author(s) This is an open access
This item is the archived peer-reviewed author-version of:
This item is the archived peer-reviewed author-version of: In vitro phase I- and phase II-drug metabolism in the liver of juvenile and adult Göttingen minipigs Reference: Van Peer Els, Jacobs Frank, Snoeys
Muhammad Fawad Rasool Feras Khalil Stephanie Läer
Clin Pharmacokinet (2015) 54:943 962 DOI 10.1007/s40262-015-0253-7 ORIGINAL RESEARCH ARTICLE A Physiologically Based Pharmacokinetic Drug Disease Model to Predict Carvedilol Exposure in Adult and Paediatric
CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: Interindividual differences in these contributions
DMD Fast This article Forward. has not Published been copyedited on and August formatted. 31, The 2005 final version as doi:10.1124/dmd.105.006254 may differ from this version. CYP2A6 and CYP2B6 are involved
Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions
AIDS Rev. 2013;15:87 101 Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions Clinical Perspective on Drug Drug Interactions with the Non-nucleoside Reverse Transcriptase Inhibitor Rilpivirine Herta
Pathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine S
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2008/05/07/dmd.107.019562.dc1 0090-9556/08/3608-1637 1649$20.00 DRUG METABOLISM AND DISPOSITION Vol. 36,
COPYRIGHTED MATERIAL IN VITRO EVALUATION OF METABOLIC DRUG DRUG INTERACTIONS: CONCEPTS AND PRACTICE ALBERT P. LI
1 IN VITRO EVALUATION OF METABOLIC DRUG DRUG INTERACTIONS: CONCEPTS AND PRACTICE ALBERT P. LI CONTENTS 1.1 Introduction 2 1.2 Mechanisms of Adverse Drug Drug Interactions 4 1.2.1 Pharmacological Interactions
METABOLISM OF ( )- AND ( )-LIMONENES TO RESPECTIVE CARVEOLS AND PERILLYL ALCOHOLS BY CYP2C9 AND CYP2C19 IN HUMAN LIVER MICROSOMES
0090-9556/02/3005-602 607$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 5 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 641/981193 DMD 30:602 607, 2002 Printed
DMD# human UDP-glucuronosyltransferases, species differences, and interaction potential
DMD This Fast article Forward. has not been Published copyedited and on formatted. April 9, The 2010 final as version doi:10.1124/dmd.109.031864 may differ from this version. Regioselective glucuronidation
Cryopreserved Human Hepatocytes (Cat # HP-F)
Certificate of Analysis Cryopreserved Human Hepatocytes (Cat # HP-F) This CoA represents a single Lot specific batch of cells. For details of current Lots available please contact us. Lot#: H0434 Gender
In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters s
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2013/01/04/dmd.112.049668.dc1 1521-009X/41/3/668 681$25.00 http://dx.doi.org/10.1124/dmd.112.049668 DRUG
An Evaluation of the CYP450 Inhibition Potential of Lisdexamfetamine in. Human Liver Microsomes
DMD Fast This Forward. article has not Published been copyedited on and October formatted. 11, The 2006 final version as doi:10.1124/dmd.106.011973 may differ from this version. TITLE PAGE An Evaluation
Optimization of Experimental Conditions of Automated Glucuronidation Assays in
Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes using a Cocktail Approach and Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry
THE EFFECT OF INCUBATION CONDITIONS ON THE ENZYME KINETICS OF UDP-GLUCURONOSYLTRANSFERASES
0090-9556/03/3106-762 767$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 6 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 1031/1067920 DMD 31:762 767, 2003 Printed
Glucuronidation Converts Gemfibrozil to a Potent, Metabolism-Dependent. Inhibitor of CYP2C8: Implications for Drug-Drug Interactions
DMD Fast This Forward. article has not Published been copyedited on and November formatted. The 18, final 2005 version as may doi:10.1124/dmd.105.007633 differ from this version. Glucuronidation Converts
INVOLVEMENT OF CYP2E1 AS A LOW-AFFINITY ENZYME IN PHENACETIN O-DEETHYLATION IN HUMAN LIVER MICROSOMES
0090-9556/99/2708-0860 865$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 8 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. INVOLVEMENT OF
Received December 14, 2009; accepted March 19, 2010
0090-9556/10/3807-1211 1217$20.00 DRUG METABOLISM AND DISPOSITION Vol. 38, No. 7 Copyright 2010 by The American Society for Pharmacology and Experimental Therapeutics 31625/3591857 DMD 38:1211 1217, 2010
Valproate Case 1: Pharmacokinetics Jose de Leon, MD
Valproate Case 1: Pharmacokinetics 2-12-16 Jose de Leon, MD 1. Valproate Case 1 J Clin Psychopharmacology 2009;29:509-11 http://www.ncbi.nlm.nih.gov/pubmed/19745660 Educational Objectives At the conclusion
BIOMARKERS AND TOXICITY MECHANISMS 07 Mechanisms Metabolism & Detoxification. Luděk Bláha, PřF MU, RECETOX
BIOMARKERS AND TOXICITY MECHANISMS 07 Mechanisms Metabolism & Detoxification Luděk Bláha, PřF MU, RECETOX www.recetox.cz Metabolism and detoxification Chemicals enter body... mostly via food Pass directly
Probe substrate and enzyme source-dependent inhibition of UDPglucuronosyltransferase
Probe substrate and enzyme source-dependent inhibition of UDPglucuronosyltransferase (UGT) 1A9 by wogonin Chengcheng Gao, Rui Xie, Tianheng Ma, Wei Yan, Liqun Pang* Department of Gastroenterology, Huai
Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity
et al. DOI:1.146/j.1365-2125.3.197.x British Journal of Clinical Pharmacology Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity
Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome
ORIGINAL ARTICLE Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome Ryoichi Fujiwara & Tomoo Itoh School of Pharmacy, Kitasato University,
Effects of Liver Disease on Pharmacokinetics
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 31, 2013 National Institutes of Health Clinical Center 1 GOALS of Effects of Liver
Drug Metabolizing Enzymes and Reaction-Phenotyping
Drug Metabolizing Enzymes and Reaction-Phenotyping Carl D. Davis, Ph.D. Pharmaceutical Candidate Optimization Metabolism and Pharmacokinetics Bristol-Myers Squibb Pharmaceutical Research Institute Wallingford,
TECHNICAL BULLETIN. Primary Human Hepatocytes LifeNet Health
Primary Human Hepatocytes LifeNet Health Catalog Number: MTOXH1000 - Cryoplateable Primary Human Hepatocytes MTOXH1001 - Cryopreserved Primary Human Hepatocytes Metabolism Qualified Suspension Grade MTOXH1002
Epidiolex (cannabidiol) NEW PRODUCT SLIDESHOW
Epidiolex (cannabidiol) NEW PRODUCT SLIDESHOW Introduction Brand name: Epidiolex Generic name: Cannabidiol Pharmacological class: Cannabinoid Strength and Formulation: 100mg/mL; oral soln; strawberry-flavored;
Characterization of nuciferine metabolism by P450 enzymes and uridine diphosphate glucuronosyltransferases in liver microsomes from humans and animals
(2010) 31: 1635 1642 2010 CPS and SIMM All rights reserved 1671-4083/10 $32.00 Original Article Characterization of nuciferine metabolism by P450 enzymes and uridine diphosphate glucuronosyltransferases
IN VITRO IDENTIFICATION OF THE HUMAN CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF R( )- AND S( )-CARVEDILOL
0090-9556/97/2508-0970 977$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 25, No. 8 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. IN VITRO IDENTIFICATION
Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic
Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes ** Lei Cao, David J Greenblatt, Awewura Kwara Graduate Program in Pharmacology
Months Years. Centimeters Inches Missing Reason: Not Done Unknown. Kilograms Pounds Missing Reason: Not Done Unknown. Female Male Unknown
Form 2: Donor Print this Form t Started 1 2 Transplant Date Donor Age Indicate age in months, days, or years Days Months Years Donor Date of Birth Height and Weight 3 Donor Height Centimeters Inches t
Metabolic Profile, Enzyme Kinetics, and Reaction Phenotyping of β Lapachone Metabolism in Human Liver and Intestine in Vitro
pubs.acs.org/molecularpharmaceutics Metabolic Profile, Enzyme Kinetics, and Reaction Phenotyping of β Lapachone Metabolism in Human Liver and Intestine in Vitro Xuefang Cheng, Fang Liu, Tingting Yan, Xueyan
AND LIVER MICROSOMAL P-450 PROFILES
0090-9556/99/2706-0655 666$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 6 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. DEVELOPMENT OF
Octanol / Water Partitioning Coefficient logp and ClogP
Lipid solubility and the brain uptake of compounds Higher the Kow, the greater the brain uptake Specific carriers can facilitate brain uptake (glucose, lucine, dopa) Binding to plasma proteins can reduce
CYTOCHROME P450 3A-MEDIATED METABOLISM OF BUSPIRONE IN HUMAN LIVER MICROSOMES
0090-9556/05/3304-500 507$20.00 DRUG METABOLISM AND DISPOSITION Vol. 33, No. 4 Copyright 2005 by The American Society for Pharmacology and Experimental Therapeutics 836/1197409 DMD 33:500 507, 2005 Printed
Characterization of human cytochrome P-450 enzymes involved in the metabolism of. the piperidine-type phenothiazine neuroleptic thioridazine
DMD Fast This Forward. article has not Published been copyedited on and November formatted. The 4, final 2005 version as doi:10.1124/dmd.105.006445 may differ from this version. DMD #6445 Characterization
Evaluation of Cryopreserved Human Hepatocytes as an Alternative In Vitro System to
DMD Fast This Forward. article has not Published been copyedited on and November formatted. The 28, final 2006 version as may doi:0.24/dmd.06.0569 differ from this version. Title Page Evaluation of Cryopreserved
Metabolism Studies of Desvenlafaxine
Journal of Bioequivalence & Bioavailability ISSN: 0975-0851 Journal of B ioequivalence & Bioavailability DeMaio et al. 2011, 3:7 DOI: 10.4172/ Research Article Open Open Access Metabolism Studies of Desvenlafaxine
Joan Eilstein. Metabolizing Enzymes in Human Skin. from SkinEthic TM. ADMET - Metabolism. L OREAL Advanced Research
Update in the Characterization ti of Metabolizing Enzymes in Human Skin and Reconstructed t Human Skin Models from SkinEthic TM Joan Eilstein ADMET - Metabolism Predictive Methods and Models Development
METABOLISM OF MK-0524, A DP1 ANTAGONIST, IN MICROSOMES AND HEPATOCYTES FROM PRECLINICAL SPECIES AND HUMANS
DMD Fast This Forward. article has not Published been copyedited on and November formatted. The 28, final 2006 version as may doi:10.1124/dmd.106.011551 differ from this version. METABLISM F MK-0524, A
Comparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization?
Comparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization? Brian Ogilvie, Ph.D. VP Scientific Consulting XenoTech, LLC bogilvie@xenotechllc.com 14 Jun, 2018
Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data
pubs.acs.org/crt Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data Nina Isoherranen,* Justin D. Lutz, Sophie
Andrew Rowland, Kathleen M. Knights, Peter I. Mackenzie, and John O. Miners
0090-9556/08/3606-1056 1062$20.00 DRUG METABOLISM AND DISPOSITION Vol. 36, No. 6 Copyright 2008 by The American Society for Pharmacology and Experimental Therapeutics 21105/3344446 DMD 36:1056 1062, 2008
Keywords ethinyl estradiol/norethindrone, isavuconazole, ketoconazole, midazolam, rifampin
Original Manuscript Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/ Norethindrone in Healthy Adults Clinical Pharmacology
Drug Interactions, from bench to bedside
Drug Interactions, from bench to bedside Candidate to Market, The Paterson Institute for Cancer Research, Manchester, UK Michael Griffin PhD Overview of presentation To understand the importance of drug-drug
Research Article Selective Inhibition of Bakuchicin Isolated from Psoralea corylifolia on CYP1A in Human Liver Microsomes
Evidence-Based Complementary and Alternative Medicine Volume 216, Article ID 5198743, 7 pages http://dx.doi.org/1.1155/216/5198743 Research Article Selective Inhibition of Bakuchicin Isolated from Psoralea
Novel Hepatocyte Technologies for the Evaluation of Adverse Drug Properties
Novel Hepatocyte Technologies for the Evaluation of Adverse Drug Properties Albert P. Li, Ph. D., President and CEO In Vito ADMET Laboratories Inc. Columbia, MD and Malden, MA lialbert@invitroadmet.com
Pediatric Drug Development Current Challenges
Pediatric Drug Development Current Challenges Robert Ward, MD, FAAP, FCP Professor Emeritus, Pediatrics Founder Univ Utah Pediatric Pharmacology Program Former Attending Neonatologist University of Utah
Characterization of the In Vitro and In Vivo Metabolism and Disposition and P450. Inhibition/Induction Profile of Saxagliptin in Human
DMD This Fast article Forward. has not been Published copyedited on and formatted. April 10, The 2012 final as version doi:10.1124/dmd.112.045450 may differ from this version. Characterization of the In
Are health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies
Are health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies David Gurwitz Sackler Faculty of Medicine, Tel-Aviv University, Israel OECD,
Drug Metabolism Letters
Drug Metabolism Letters 83 Send Orders for Reprints to reprints@benthamscience.ae Drug Metabolism Letters, 216, 1, 83-9 ISSN: 1872-3128 eissn: 1874-758 Efficiency in Drug Discovery: Liver S9 Fraction Assay
Supplemental Information
Supplemental Information Article Title:The Proton Pump Inhibitor, Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Co-Administration with